Search Clinical Trials
By Condition
By Location (USA)
By Location (Other)
By Sponsor
Resources
Privacy Policy
About Us
Disclaimer
Novel Epothilone plus Capecitabine versus Capecitabine Alone in Patients with Advanced Breast Cancer Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or professional assistance by using a genuine doctor. We aren't mDs. Always consult your physician about Novel Epothilone plus Capecitabine versus Capecitabine Alone in Patients with Advanced Breast Cancer conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Novel Epothilone plus Capecitabine versus Capecitabine Alone in Patients with Advanced Breast Cancer Clinical research trials and Novel Epothilone plus Capecitabine versus Capecitabine Alone in Patients with Advanced Breast Cancer health trials occur in a lot of of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the potency of new does drugs. The role of the studies / undertakings is to figure out specific human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all sorts of conditions, including Novel Epothilone plus Capecitabine versus Capecitabine Alone in Patients with Advanced Breast Cancer. Novel Epothilone plus Capecitabine versus Capecitabine Alone in Patients with Advanced Breast Cancer Clinical Trials and other clinical trials permit volunteers to get medical treatment choices before they are available to the general public. Many times the test subjects get professional assistance for free of charge, and occasionally they are compensated for their time. Sometimes there is a cost for a Novel Epothilone plus Capecitabine versus Capecitabine Alone in Patients with Advanced Breast Cancer clinical trial. Human subjects often get the best healthcare possible for their Novel Epothilone plus Capecitabine versus Capecitabine Alone in Patients with Advanced Breast Cancer condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, medical hazards (perhaps life-threatening), and/or the treatment being ineffectual. Trials are federally governed with exacting guidelines to protect clinical trials patients.

Home > "N" Clinical Trials Conditions > Novel Epothilone plus Capecitabine versus Capecitabine Alone in Patients with Advanced Breast Cancer

Novel Epothilone plus Capecitabine versus Capecitabine Alone in Patients with Advanced Breast Cancer



Novel Epothilone plus Capecitabine versus Capecitabine Alone in Patients with Advanced Breast Cancer

For Condition: Metastatic breast cancer
Status: Recruiting
Sponsor(s): Bristol-Myers Squibb ,
Synopsis: The purpose of this clinical research study is to learn if BMS-247550 added to the approved therapy of capecitabine is better than capecitabine alone in shrinking or slowing the growth of the cancer in women with metastatic breast cancer who are resistant to taxane and received anthracycline chemotherapy. The safety of this treatment will also be studied.
Details:
Eligibility:
Study Type:
  Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Female
Protocol Entry Criteria: - Patients must have recieved either 2 or 3 prior chemotherapy regimens including adjuvant or neoadjuvant therapy (At least one regimen given in the metastatic setting). - Prior treatment must have included both an anthracycline (i.e., doxorubicin or epirubicin) and a taxane (i.e., paclitaxel or docetaxel). - Patients must have recieved a minimum cumulative dose of anthracycline or must be resistant to an anthracycline. - Patients must be resistant to taxane therapy. - Patients may not have any history of brain and/or leptomeningeal metastases. - Patients may not have CTC Grade 2 or greater neuropathy (motor or sensory). - Patients may have not have had prior treatment with an epothilone and/or capecitabine (i.e., Xeloda)
Total Enrollment: 

Location and Contact Information:

BMS Call Center *Recruiting*
Princeton,  New Jersey,  08540
United States
Recruiting Locator:  104 1-866-892-1BMS


Additional Information:
Study ID Numbers:
  CA163-046; 
Study Start Date: 
Record last reviewed: May 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00080301

Other Metastatic Breast Cancer Studies:
1. Capecitabine (Xeloda) With Or Without GW572016 For Women With Refractory Advanced Or Metastatic Breast Cancer

2. Novel Epothilone plus Capecitabine versus Capecitabine Alone in Patients with Advanced Breast Cancer

3. Phase 2 randomized, placebo-controlled, double blind study of study drug in combination with Docetaxel versus Docetaxel alone for patients with Metastatic Breast Cancer.

4. GW572016 For Treatment Of Refractory Metastatic Breast Cancer

5. Paclitaxel With Or Without GW572016 As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer

Related Studies:

Other Metastatic breast cancer Clinical Trials
Other New Jersey Clinical Trials
Other Princeton Clinical Trials

Novel Epothilone plus Capecitabine versus Capecitabine Alone in Patients with Advanced Breast Cancer

Modify your Search

  Other Metastatic breast cancer Clinical Trials
  Other New Jersey Clinical Trials
  Other Princeton Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103